| __timestamp | Dyne Therapeutics, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 1145000000 | 9216000000 |
| Thursday, January 1, 2015 | 2028000000 | 8296000000 |
| Friday, January 1, 2016 | 2281000000 | 10044000000 |
| Sunday, January 1, 2017 | 2932000000 | 11560000000 |
| Monday, January 1, 2018 | 24000 | 10558000000 |
| Tuesday, January 1, 2019 | 271000 | 9351000000 |
| Wednesday, January 1, 2020 | 700000 | 8933000000 |
| Friday, January 1, 2021 | 1088000 | 8284000000 |
| Saturday, January 1, 2022 | 3345000 | 7952000000 |
| Sunday, January 1, 2023 | 2461000 | 8200000000 |
| Monday, January 1, 2024 | 8480000000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. This analysis delves into the cost of revenue trends for Teva Pharmaceutical Industries Limited and Dyne Therapeutics, Inc. over the past decade. From 2014 to 2023, Teva consistently maintained a high cost of revenue, peaking in 2017 with a 25% increase from 2014. In contrast, Dyne Therapeutics experienced significant fluctuations, with a dramatic drop in 2018, where costs plummeted by over 99% compared to the previous year. This volatility highlights the challenges faced by emerging biotech firms. By 2023, Teva's cost of revenue stabilized around 8.2 billion, while Dyne's costs showed a modest recovery. These insights underscore the contrasting financial landscapes of established pharmaceutical giants and innovative biotech startups, offering a glimpse into their strategic financial management.
Cost of Revenue: Key Insights for Novo Nordisk A/S and Dyne Therapeutics, Inc.
Merck & Co., Inc. vs Teva Pharmaceutical Industries Limited: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Limited's Expenses
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Insmed Incorporated
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and ACADIA Pharmaceuticals Inc.
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Vericel Corporation
Bio-Techne Corporation vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Catalent, Inc. vs Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and Dyne Therapeutics, Inc.
Cost of Revenue Comparison: Jazz Pharmaceuticals plc vs Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Pharming Group N.V. and Dyne Therapeutics, Inc.'s Expenses